350 related articles for article (PubMed ID: 25392322)
1. Newly produced T and B lymphocytes and T-cell receptor repertoire diversity are reduced in peripheral blood of fingolimod-treated multiple sclerosis patients.
Chiarini M; Sottini A; Bertoli D; Serana F; Caimi L; Rasia S; Capra R; Imberti L
Mult Scler; 2015 May; 21(6):726-34. PubMed ID: 25392322
[TBL] [Abstract][Full Text] [Related]
2. Fingolimod does not impair T-cell release from the thymus and beneficially affects Treg function in patients with multiple sclerosis.
Haas J; Schwarz A; Korporal-Kunke M; Jarius S; Wiendl H; Kieseier BC; Wildemann B
Mult Scler; 2015 Oct; 21(12):1521-32. PubMed ID: 25583847
[TBL] [Abstract][Full Text] [Related]
3. Treatment effects of fingolimod in multiple sclerosis: Selective changes in peripheral blood lymphocyte subsets.
Hjorth M; Dandu N; Mellergård J
PLoS One; 2020; 15(2):e0228380. PubMed ID: 32012202
[TBL] [Abstract][Full Text] [Related]
4. Impact of fingolimod on CD4+ T cell subset and cytokine profile of relapsing remitting multiple sclerosis patients.
Kürtüncü M; Yılmaz V; Akçay Hİ; Türkoğlu R; Altunrende B; Çınar SA; Ulusoy C; Gündüz T; İçöz S; Kasap M; Çalışkan Z; Ötünç G; Eraksoy M; Tüzün E
J Neuroimmunol; 2019 Dec; 337():577065. PubMed ID: 31526917
[TBL] [Abstract][Full Text] [Related]
5. Peripheral accumulation of newly produced T and B lymphocytes in natalizumab-treated multiple sclerosis patients.
Zanotti C; Chiarini M; Serana F; Sottini A; Garrafa E; Torri F; Caimi L; Rasia S; Capra R; Imberti L
Clin Immunol; 2012 Oct; 145(1):19-26. PubMed ID: 22892399
[TBL] [Abstract][Full Text] [Related]
6. Characterization of CD4+ and CD8+ T Cell Subsets and Interferon Regulatory Factor 4 (IRF4) in MS Patients Treated with Fingolimod (FTY-720): A Follow-up Study.
Laribi B; Sahraian MA; Shekarabi M; Emamnejad R; Marzban M; Sadaghiani S; Izad M
Iran J Allergy Asthma Immunol; 2018 Aug; 17(4):346-360. PubMed ID: 30537798
[TBL] [Abstract][Full Text] [Related]
7. Baseline Differences in Minor Lymphocyte Subpopulations may Predict Response to Fingolimod in Relapsing-Remitting Multiple Sclerosis Patients.
Teniente-Serra A; Hervás JV; Quirant-Sánchez B; Mansilla MJ; Grau-López L; Ramo-Tello C; Martínez-Cáceres EM
CNS Neurosci Ther; 2016 Jul; 22(7):584-92. PubMed ID: 27080413
[TBL] [Abstract][Full Text] [Related]
8. Fingolimod therapy modulates circulating B cell composition, increases B regulatory subsets and production of IL-10 and TGFβ in patients with Multiple Sclerosis.
Blumenfeld S; Staun-Ram E; Miller A
J Autoimmun; 2016 Jun; 70():40-51. PubMed ID: 27055778
[TBL] [Abstract][Full Text] [Related]
9. Renewal of the T-cell compartment in multiple sclerosis patients treated with glatiramer acetate.
Chiarini M; Sottini A; Ghidini C; Zanotti C; Serana F; Rottoli M; Zaffaroni M; Bergamaschi R; Cordioli C; Capra R; Imberti L
Mult Scler; 2010 Feb; 16(2):218-27. PubMed ID: 20007428
[TBL] [Abstract][Full Text] [Related]
10. Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod.
Fragoso YD; Spelman T; Boz C; Alroughani R; Lugaresi A; Vucic S; Butzkueven H; Terzi M; Havrdova E; Horakova D; Granella F; Olascoaga J; Sánchez-Menoyo JL; Pucci E; Barnett M; Brooks JBB; Haartsen J;
Mult Scler Relat Disord; 2018 Jan; 19():105-108. PubMed ID: 29182993
[TBL] [Abstract][Full Text] [Related]
11. Opposite effects of interferon-β on new B and T cell release from production sites in multiple sclerosis patients.
Zanotti C; Chiarini M; Serana F; Capra R; Rottoli M; Rovaris M; Cavaletti G; Clerici R; Rezzonico M; Caimi L; Imberti L
J Neuroimmunol; 2011 Dec; 240-241():147-50. PubMed ID: 22078237
[TBL] [Abstract][Full Text] [Related]
12. Reconstitution of the peripheral immune repertoire following withdrawal of fingolimod.
Ghadiri M; Fitz-Gerald L; Rezk A; Li R; Nyirenda M; Haegert D; Giacomini PS; Bar-Or A; Antel J
Mult Scler; 2017 Aug; 23(9):1225-1232. PubMed ID: 28749311
[TBL] [Abstract][Full Text] [Related]
13. Compositional changes of B and T cell subtypes during fingolimod treatment in multiple sclerosis patients: a 12-month follow-up study.
Claes N; Dhaeze T; Fraussen J; Broux B; Van Wijmeersch B; Stinissen P; Hupperts R; Hellings N; Somers V
PLoS One; 2014; 9(10):e111115. PubMed ID: 25360562
[TBL] [Abstract][Full Text] [Related]
14. Age-Related Lymphocyte Output During Disease-Modifying Therapies for Multiple Sclerosis.
Paghera S; Sottini A; Previcini V; Capra R; Imberti L
Drugs Aging; 2020 Oct; 37(10):739-746. PubMed ID: 32761321
[TBL] [Abstract][Full Text] [Related]
15. Peripheral blood T cell dynamics predict relapse in multiple sclerosis patients on fingolimod.
Song ZY; Yamasaki R; Kawano Y; Sato S; Masaki K; Yoshimura S; Matsuse D; Murai H; Matsushita T; Kira J
PLoS One; 2014; 10(4):e0124923. PubMed ID: 25919001
[TBL] [Abstract][Full Text] [Related]
16. Lymphocyte subsets as biomarkers of therapeutic response in Fingolimod treated Relapsing Multiple Sclerosis patients.
Paolicelli D; Manni A; D'Onghia M; Direnzo V; Iaffaldano P; Zoccolella S; Di Lecce V; Tortorella C; Specchia G; Trojano M
J Neuroimmunol; 2017 Feb; 303():75-80. PubMed ID: 28043652
[TBL] [Abstract][Full Text] [Related]
17. Antigen-shift in varicella-zoster virus-specific T-cell immunity over the course of Fingolimod-treatment in relapse-remitting multiple sclerosis patients.
Matko S; Akgün K; Tonn T; Ziemssen T; Odendahl M
Mult Scler Relat Disord; 2020 Feb; 38():101859. PubMed ID: 31855843
[TBL] [Abstract][Full Text] [Related]
18. Fingolimod reduces CXCR4-mediated B cell migration and induces regulatory B cells-mediated anti-inflammatory immune repertoire.
Blumenfeld-Kan S; Staun-Ram E; Miller A
Mult Scler Relat Disord; 2019 Sep; 34():29-37. PubMed ID: 31228713
[TBL] [Abstract][Full Text] [Related]
19. Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS.
Kowarik MC; Pellkofer HL; Cepok S; Korn T; Kümpfel T; Buck D; Hohlfeld R; Berthele A; Hemmer B
Neurology; 2011 Apr; 76(14):1214-21. PubMed ID: 21464424
[TBL] [Abstract][Full Text] [Related]
20. Fingolimod increases CD39-expressing regulatory T cells in multiple sclerosis patients.
Muls N; Dang HA; Sindic CJ; van Pesch V
PLoS One; 2014; 9(11):e113025. PubMed ID: 25411844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]